NEOTHERAPEUTICS (NEOT) (NEOTW) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW)

NEOT 1.919

+4.3%

Jan 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: psyched who wrote (591)	11/10/1998 1:10:00 PM
From: Marty	Read Replies (2) of 705

What did the CBS program say about NEOT & Dr. Glasky? I can't ever figure the price action of this stock. Today is probably a "Buy on the rumor ..." kind of thing. I believe that this is just one of those stocks that you have to accumulate when you think it is at a good buying range and put the shares away until the ship comes in. As we saw the last week or so, the bigger danger is to be out of the stock and missing the ride when it goes up. I am personally confidant from following it for so long that some day they will be worth A LOT. I am going to TRY not to aggravate myself about the down days in the meantime as long as there is progress and the Company continues to let us know what is going on in a way that is understandable to those of us without a technical biomed background. Here is a copy of a post on the Motley Fool NEOT board: News items in today's Investor Business Daily regarding Alzheimer's disease. "Waiting just one month to put Alzheimer's patients in a home could save $1.12 billion a year, says a study in the journal Health Affairs." "Alzheimer's affects about 1.9 million Americans. Treatment costs $28,000 a year each." This is a very expensive disease for anyone affected, as well as for Medicare. Any company with the promise of a really effective treatment drug should be given special fast track consideration by the FDA because of all the agony and expense it will save. It will be very profitable to the developers who are in the market first with an effective drug and NEOT is far ahead of everyone else in human testing with a very promising family of drugs for treatment of Alzheimer's disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next